Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Prostate Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · October 19, 2022

Different Sensitivity to PARP Inhibitors in Patients With Prostate Cancer Harboring BRCA1 vs BRCA2 Mutations

Frontiers in Oncology


Additional Info

Frontiers in Oncology
Genomic landscape of advanced prostate cancer patients with BRCA1 versus BRCA2 mutations as detected by comprehensive genomic profiling of cell-free DNA
Front Oncol 2022 Sep 15;12(xx)966534, U Swami, RM Zimmerman, RH Nussenzveig, EJ Hernandez, Y Jo, N Sayegh, S Wesolowski, LA Kiedrowski, PC Barata, GH Lemmon, MA Bilen, EI Heath, L Nandagopal, HM Babiker, SK Pal, M Lilly, BL Maughan, B Haaland, M Yandell, O Sartor, N Agarwal

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading